Oyebimpe Oluyemisi Adesina, M.D., M.S. for UC Davis Health

Oyebimpe Oluyemisi Adesina, M.D., M.S.

Oyebimpe Oluyemisi Adesina, M.D., M.S.

Assistant Professor

To see if Oyebimpe Oluyemisi Adesina is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Reviews

Specialties

Hematology

Hemoglobinopathies

Department

Internal Medicine

Locations and Contact

UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center
4501 X St.
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Phone

916-734-5959

Clinic Fax

916-457-4542

Clinic Referral Phone

800-2-UCDAVIS (800-282-3284)

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

In my clinical practice, I focus on evidence-based diagnosis and management of a broad range of non-malignant hematologic conditions. I primarily treat acute and chronic complications of sickle cell disease in adults. My passion for caring for adults with sickle cell disease stems from my desire to serve this vulnerable patient population, many of whom live with severe chronic pain and face immense psychosocial stressors in their pursuit of equitable healthcare. I work diligently to gain my patients' trust because many have been traumatized by structural racism in a healthcare system that invalidates their pain and other health needs. I consistently model empathetic and thorough patient care to my clinical team because I strongly believe that every patient deserves to be treated with respect and compassion. I want my clinical practice, teaching, and scholarly work to inspire medical trainees (especially those who are underrepresented in medicine like I am) to reach for academic excellence, while practicing socially responsible clinical care and engaging in patient-centered research.

Clinical Interests

Dr. Adesina is an adult hematologist who specializes in the diagnosis and treatment of adults with non-malignant hematologic disorders. She has clinical expertise in the care of adults with sickle cell disease, with an emphasis on multi-modal management to improve her patients' overall health-related quality of life. Her research focuses on the diagnosis and treatment of musculoskeletal complications of sickle cell disease, and how these contribute to the development of chronic sickle cell pain.

Research/Academic Interests

Dr. Adesina primarily researches the pathophysiology of osteonecrosis, an understudied and debilitating skeletal complication of sickle cell disease that causes severe chronic pain and results in high healthcare utilization. Her goal is to develop safe and effective non-surgical interventions to alleviate bone pain, retard joint deterioration, and improve the overall health-related quality of life in people with sickle cell-related osteonecrosis. She studies musculoskeletal development in children and adolescents enrolled in the Sickle Cell Clinical Research and Intervention Program (SCCRIP), which is a large, multi-center, lifespan cohort study that is maintained at St. Jude Children's Research Hospital in Memphis, TN. She also studies the epidemiology of risk factors and health outcomes of sickle cell-related complications, in collaboration with population health scientists from the UC Davis Center for Oncology Hematology Outcomes Research Training group.

Division

Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.S., Chemistry, UC Berkeley, Berkeley CA 2002

Medical School

M.D., UC San Francisco, San Francisco CA 2008

Other School

M.S., Clinical Research and Epidemiology, Stanford University, Stanford CA 2016

Internship

Internal Medicine, Stanford University Hospital & Clinics, Stanford CA 2008-2009

Residency

Internal Medicine, Stanford University Hospital & Clinics, Stanford CA 2009-2011

Fellowship

Hematology and Oncology, Stanford University Hospital & Clinics, Stanford CA 2012-2015

NHLBI K23 Mentored Career Development Award (2021-2026),

Doris Duke Charitable Foundation, Clinical Scientist Development Award Recipient (2021-2023), 2020

NICHD R21 Exploratory/Development Research Grant Award (2021-2022),

K12 Benign Hematology Research Scholar, NHLBI- University of Washington (2017-2018),

KL2 Mentored Career Development Award Recipient, SPECTRUM (CTSA)-Stanford University (2015-2016),

Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022 Jan 11;6(1):307-320. doi:10.1182/bloodadvances.2021005590. PMID:34649273.

Adesina OO, Jenkins IC, Wu QV, Fung EB, Narla RR, Lipkin EW, Mahajan K, Konkle BA, Kruse-Jarres R. Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease. Blood Cells Mol Dis. 2020 Feb;80:102369. doi:10.1016/j.bcmd.2019.102369. Epub 2019 Oct 24. PMID:31677454.

Johnston EE, Adesina OO, Alvarez E, Amato H, Paulukonis S, Nichols A, Chamberlain LJ, Bhatia S. Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach. J Palliat Med. 2020 Jan;23(1):24-32. doi:10.1089/jpm.2018.0649. Epub 2019 Aug 7. PMID:31390292.

Adesina OO, Neumayr LD. Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):351-358. doi:10.1182/hematology.2019000038. PMID:31808856.

Adesina OO, Gurney JG, Kang G, Villavicencio M, Hodges JR, Chemaitilly W, Kaste SC, Zemel BS, Hankins JS. Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results. Blood Adv. 2019 May 14;3(9):1476-1488. doi:10.1182/bloodadvances.2018026047. PMID:31072833.

Hankins JS, Estepp JH, Hodges JR, Villavicencio MA, Robison LL, Weiss MJ, Kang G, Schreiber JE, Porter JS, Kaste SC, Saving KL, Bryant PC, Deyo JE, Nottage KA, King AA, Brandow AM, Lebensburger JD, Adesina O, Chou ST, Zemel BS, Smeltzer MP, Wang WC, Gurney JG. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatr Blood Cancer. 2018 Sep;65(9):e27228. doi:10.1002/pbc.27228. Epub 2018 May 24. PMID:29797644.

Hilt H, Adesina OO. Hyperhemolysis syndrome in a pregnant woman with sickle cell anemia. Transfusion Management of the Obstetrical Patient- A Clinical Casebook. 2018;17:155-161.

Stack SW, Adesina OO, Shobha W. Sickle Cell Disease. Perioperative Medicine Consult Handbook, 3rd Edition. 2020;27:227-231.

Adesina O, Brunson A, Keegan THM, Wun T. Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. Blood Adv. 2017 Jul 11;1(16):1287-1295. doi:10.1182/bloodadvances.2017005256. PMID:29296770.

Adesina OO, Hoppe CC and Hankins JS. It takes a village: A fellow’s narrative on building a strong network of mentors. The Hematologist. Nov/Dec 2015 Nov/Dec;12(6):13.